Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics

Marco A. Ramírez-Ortiz; Citlali Lara-Molina; Dina Villanueva-García; Mónica Villa-Guillén; Luis Jasso-Gutiérrez; Leyla Carolina Padilla-Sierra; Violeta Robredo-Torres; Juan Carlos Bravo-Ortiz; José Alfonso Gutiérrez Padilla; Eusebio Angulo Castellanos; Javier Mancilla Ramírez; Manuel Bernardo Salgado-Valladares; María Graciela Hernández-Peláez; Leonor Hernández Salazar; Luis Porfirio Orozco Gómez; Luz Consuelo Zepeda-Romero

Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics

Translated title of the contribution: Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics

Marco A. Ramírez-Ortiz, Citlali Lara-Molina, Dina Villanueva-García, Mónica Villa-Guillén, Luis Jasso-Gutiérrez, Leyla Carolina Padilla-Sierra, Violeta Robredo-Torres, Juan Carlos Bravo-Ortiz, José Alfonso Gutiérrez Padilla, Eusebio Angulo Castellanos, Javier Mancilla Ramírez, Manuel Bernardo Salgado-Valladares, María Graciela Hernández-Peláez, Leonor Hernández Salazar, Luis Porfirio Orozco Gómez, Luz Consuelo Zepeda-Romero

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.

Translated title of the contribution	Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics
Original language	English
Pages (from-to)	344-350
Number of pages	7
Journal	Boletin Medico del Hospital Infantil de Mexico
Volume	70
Issue number	5
State	Published - Sep 2013
Externally published	Yes

Keywords

Antiangiogenics
Intravitreal injections
Retinopathy of prematurity

Cite this

Ramírez-Ortiz, M. A., Lara-Molina, C., Villanueva-García, D., Villa-Guillén, M., Jasso-Gutiérrez, L., Padilla-Sierra, L. C., Robredo-Torres, V., Bravo-Ortiz, J. C., Padilla, J. A. G., Castellanos, E. A., Ramírez, J. M., Salgado-Valladares, M. B., Hernández-Peláez, M. G., Salazar, L. H., Gómez, L. P. O., & Zepeda-Romero, L. C. (2013). Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics. Boletin Medico del Hospital Infantil de Mexico, 70(5), 344-350.

@article{6b276b477b06447e8d095a8af4533840,

title = "Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics",

abstract = "The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.",

keywords = "Antiangiogenics, Intravitreal injections, Retinopathy of prematurity",

author = "Ram{\'i}rez-Ortiz, {Marco A.} and Citlali Lara-Molina and Dina Villanueva-Garc{\'i}a and M{\'o}nica Villa-Guill{\'e}n and Luis Jasso-Guti{\'e}rrez and Padilla-Sierra, {Leyla Carolina} and Violeta Robredo-Torres and Bravo-Ortiz, {Juan Carlos} and Padilla, {Jos{\'e} Alfonso Guti{\'e}rrez} and Castellanos, {Eusebio Angulo} and Ram{\'i}rez, {Javier Mancilla} and Salgado-Valladares, {Manuel Bernardo} and Hern{\'a}ndez-Pel{\'a}ez, {Mar{\'i}a Graciela} and Salazar, {Leonor Hern{\'a}ndez} and G{\'o}mez, {Luis Porfirio Orozco} and Zepeda-Romero, {Luz Consuelo}",

year = "2013",

month = sep,

language = "Ingl{\'e}s",

volume = "70",

pages = "344--350",

journal = "Boletin Medico del Hospital Infantil de Mexico",

issn = "1665-1146",

number = "5",

}

Ramírez-Ortiz, MA, Lara-Molina, C, Villanueva-García, D, Villa-Guillén, M, Jasso-Gutiérrez, L, Padilla-Sierra, LC, Robredo-Torres, V, Bravo-Ortiz, JC, Padilla, JAG, Castellanos, EA, Ramírez, JM, Salgado-Valladares, MB, Hernández-Peláez, MG, Salazar, LH, Gómez, LPO & Zepeda-Romero, LC 2013, 'Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics', Boletin Medico del Hospital Infantil de Mexico, vol. 70, no. 5, pp. 344-350.

TY - JOUR

T1 - Retinopathy of prematurity

T2 - Controversies in the usage of intraocular antiangiogenics

AU - Ramírez-Ortiz, Marco A.

AU - Lara-Molina, Citlali

AU - Villanueva-García, Dina

AU - Villa-Guillén, Mónica

AU - Jasso-Gutiérrez, Luis

AU - Padilla-Sierra, Leyla Carolina

AU - Robredo-Torres, Violeta

AU - Bravo-Ortiz, Juan Carlos

AU - Padilla, José Alfonso Gutiérrez

AU - Castellanos, Eusebio Angulo

AU - Ramírez, Javier Mancilla

AU - Salgado-Valladares, Manuel Bernardo

AU - Hernández-Peláez, María Graciela

AU - Salazar, Leonor Hernández

AU - Gómez, Luis Porfirio Orozco

AU - Zepeda-Romero, Luz Consuelo

PY - 2013/9

Y1 - 2013/9

N2 - The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.

AB - The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.

KW - Antiangiogenics

KW - Intravitreal injections

KW - Retinopathy of prematurity

UR - http://www.scopus.com/inward/record.url?scp=84886046464&partnerID=8YFLogxK

M3 - Artículo

SN - 1665-1146

VL - 70

SP - 344

EP - 350

JO - Boletin Medico del Hospital Infantil de Mexico

JF - Boletin Medico del Hospital Infantil de Mexico

IS - 5

ER -

Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics

Abstract

Keywords

Other files and links

Fingerprint

Cite this